phosphodiesterase 5 inhibitors
Alzheimer’s groups call for urgent global focus on women’s brain health
New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment
The agreement covers the development of new lead tau morphomer candidates
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark
Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s
Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients
Lilly and Indiana University collaborate to expand clinical trial access
The five-year agreement includes a focus on R&D for Alzheimer’s disease
Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease
While the trials did not meet their primary endpoints, they highlighted important biomarker findings
Vandria announces positive phase 1 data for Alzheimer’s treatment
Trial data showed that VNA-318 has the ability to penetrate the brain
Eisai submits new drug application for subcutaneous Leqembi in Japan
LEQEMBI is a treatment for early Alzheimer’s disease
Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment
The MHRA approval for IV dosing comes following positive results from the global phase 3 trial
Lilly and WHO Foundation partner to support global dementia action plan
The partnership will provide financial support and strengthen early detection and intervention efforts
Lilly’s early Alzheimer’s disease treatment approved in the EU
Marketing authorisation follows positive late-stage trial results